Glenmark Life Sciences Name Has Been Changed to Alivus Life Sciences Ltd Effective From Jan 20, 2025

Glenmark Life Sciences, originally founded as a subsidiary of Glenmark Pharmaceuticals, specialises in developing, manufacturing, and supplying high-quality APIs to global markets. Over the years, it has built a strong reputation for advanced research, robust manufacturing, and a steadfast commitment to quality. Operating in over 80 countries, Glenmark Life Sciences is recognised for its reliability and innovation.

Glenmark Life Sciences Becomes Alivus Life Sciences

Glenmark Life Sciences has officially rebranded itself as Alivus Life Sciences Ltd., effective from January 20, 2025. This significant transformation reflects the company’s evolving vision, its commitment to excellence, and its ambition to redefine the landscape of the pharmaceutical and life sciences industries.

Glenmark Life Sciences Q2 FY25 Results

Glenmark Life Sciences reported its financial results for the Q2 FY25, recording a 15% year-on-year decline in revenue to ₹506.88 crore. The company’s net profit also fell by 20% year-on-year to ₹95.32 crore. This decline was primarily attributed to the temporary closure of its manufacturing facility in Ankleshwar, Gujarat, which affected revenue generation across various geographies. 

Despite the setback, the company remains optimistic about a recovery in the latter half of the fiscal year, supported by a robust order book and the resumption of operations at the affected facility.

Share Price and Performance 

At 12:49 PM today, Glenmark Life Sciences Ltd. shares traded at ₹1,043.15 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.